The first pathway for importation outlined in the plan would rely on a notice of proposed rulemaking to authorize importation of drugs from Canada. The second pathway would allow manufacturers to import versions of FDA-approved drugs that are sold in other countries.
HHS announced today the publication of its Safe Importation Action Plan, a document outlining 2 potential pathways to allow the importation of some drugs that were intended for foreign markets.
HHS Secretary Alex Azar said in a statement that the plan is intended to address the problem of American patients “paying exorbitantly high prices for prescription drugs that are made available to other countries at lower prices.” According to Azar, the plan “is the next important step in the Administration’s work to end foreign freeloading and put American patients first.”
The first pathway for importation outlined in the plan would rely on a notice of proposed rulemaking (NPRM) to authorize importation of drugs from Canada. States, wholesalers, and pharmacists would be allowed to submit plans outlining how they would import approved Canadian drugs for demonstration projects for HHS to review.
“The importation would occur in a manner that adequately assures the drug is what it purports to be and that meets the cost requirements of the rulemaking,” the plan states, and the demonstrations would be time-limited.
Certain conditions—regarding drug quality, record keeping, testing, and protections against counterfeiting—would have to be met, and the NPRM would list requirements and invite proposals on how those conditions would be met.
Eligible drugs would include those that are Canadian-authorized versions of FDA-approved drugs. These drugs would have to contain active pharmaceutical ingredients manufactured at facilities that also manufacture API for the FDA-approved version, and biologics (including insulins), infused drugs, and certain other drugs would be excluded from importation under this pathway.
The second pathway would allow manufacturers to import versions of FDA-approved drugs—potentially including insulins and drugs that treat rheumatoid arthritis and cancer, though HHS did not specify which products these potential inclusions might encompass—that are sold in other countries. The manufacturer would need to establish that these drugs are the same as those sold in the US by providing manufacturing records.
“The Administration has reason to believe that manufacturers might use this pathway as an opportunity to offer Americans lower cost versions of their own drugs,” the plan indicates. HHS says that it may see comments on whether manufacturers would seek to lower costs to patients under this second pathway. If costs can indeed be lowered through this approach, there may be a reduced need for the demonstration projects described in the first approach, the plan indicates.
Acting FDA Commissioner Ned Sharpless, MD, said in a statement, “We support the President and Secretary’s efforts to bring down drug prices for Americans. The FDA has a unique role to play in promoting competition that in turn can help reduce drug prices and improve access to medicine for Americans.” Sharpless added that “We’ve been keenly focused on ensuring the importation approaches we’ve outlined pose no additional risk to the public’s health and safety. We know there are many operational challenges to address through each of these pathways, and are actively working through them as we look to formally announce these policies, with opportunity for public comment, in the coming months.”
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.